- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07395232
Uno studio sull'efficacia e la sicurezza di DFL24498 nel trattamento dell'AKC
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Participants With Atopic Keratoconjunctivitis (AKC)
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study will consist of 3 periods:
- Washout period (from Day -7 ± 1 to Day 1),
- Treatment Period (from randomization through Week12) and
- Follow-up period (Weeks 13 to 16).
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
- Numero di telefono: +39 02 583 831
Luoghi di studio
-
-
-
Bologna, Italia, 40138
- Reclutamento
- IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia
-
Chieti, Italia, 66100
- Reclutamento
- Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti
-
Florence, Italia, 50134
- Reclutamento
- Azienda Ospedaliero Universitaria Careggi
-
Roma, Italia, 00161
- Reclutamento
- AOU Policlinico Umberto I
-
Roma, Italia, 00128
- Reclutamento
- Fondazione Policlinico Universitario Campus Bio-Medico
-
Verona, Italia, 37134
- Reclutamento
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Córdoba, Spagna, 14012
- Reclutamento
- METAVISION ARRUZAFA S.L. (Hospital Arruzafa)
-
Santiago de Compostela, Spagna, 15706
- Reclutamento
- Miranza Galicia
-
Valencia, Spagna, 46015
- Reclutamento
- Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM)
-
Valladolid, Spagna, 47011
- Reclutamento
- OBA - Universidad de Valladolid
-
Zaragoza, Spagna, 50009
- Reclutamento
- Hospital Universitario Miguel Servet
-
-
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32256
- Reclutamento
- Bowden Eye Associates - Southside Location
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute
-
-
Georgia
-
Morrow, Georgia, Stati Uniti, 30260
- Reclutamento
- Clayton Eye Clinical Research
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63131
- Reclutamento
- Ophthalmology Associates
-
-
New York
-
New York, New York, Stati Uniti, 10017
- Reclutamento
- NYU Langone Health - Eye Center
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke Eye Center - Ophthalmology
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38119
- Reclutamento
- Total Eye Care, PA
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Male or Female aged ≥ 10 and ≤ 65 years.
-
Diagnosis of AKC in both eyes, including the presence or medical history of the following:
- other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
- chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
-
Ocular itching of at least 50 as assessed by VAS scale.
-
Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.
-
A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).
-
If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.
Exclusion Criteria:
Participants will be excluded if any of the following criteria apply:
- Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
- Evidence of an active ocular infection in either eye.
- Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
- Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
- Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
- Participants that are anatomically monocular.
- Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.
Note: Additional protocol defined Inclusion/Exclusion criteria apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: DFL24498
Participants will be administered with DFL24498 eye drops in both eyes. |
DFL24498 will be instilled in each eye for 12 Weeks. Rescue medication may be administered as required at the Investigator discretion. |
|
Comparatore placebo: Vehicle
Participants will be administered with vehicle eye drops in both eyes. |
Rescue medication may be administered as required at the Investigator discretion. Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS).
Lasso di tempo: Baseline and at Week 6
|
The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point. |
Baseline and at Week 6
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline at week 6 in corneal epithelial fluorescein staining, scored by modified Oxford scale, in the study eye.
Lasso di tempo: Baseline and at Week 6
|
Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Examination will be performed at the slit-lamp using blue (cobalt) light. Corneal fluorescein staining will be graded according to the modified Oxford scale (7-point scale: 0, 0.5. 1, 2, 3, 4, 5). |
Baseline and at Week 6
|
|
Change from baseline at week 6 in bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100), in the study eye.
Lasso di tempo: Baseline and at Week 6
|
Bulbar conjunctival redness will be assessed at the slit-lamp examination using white light prior to vital dye instillation and graded according to the VBR 10 scale. |
Baseline and at Week 6
|
|
Change from baseline over time in ocular itching score assessed by VAS.
Lasso di tempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in ocular symptoms of itching, tearing, discomfort, mucous discharge, and photophobia on a 4-point scale (0 to 3).
Lasso di tempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Ocular symptoms are assessed using a 4-point severity scale ranging from 0 (none) to 3 (severe). Five ocular symptoms, itching, tearing, ocular discomfort (including burning, stinging, and foreign body sensation), mucous discharge, and photophobia are evaluated in the study eye. A composite symptom score is described in calculated at screening and Baseline by summing the individual symptom scores, resulting in a total score range of 0 to 15, with higher scores indicating greater symptom severity. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in corneal fluorescein staining (modified Oxford scale) in the study eye.
Lasso di tempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Corneal fluorescein staining modified Oxford scale (0-5) as per corneal dot count in each eye. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in bulbar conjunctival hyperemia assessed by VBR 10 scale (0 to 100) in the study eye.
Lasso di tempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100). |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in signs of tarsal papillary reaction, corneal neovascularization, cicatrizing conjunctivitis and blepharitis on a 4-point scale (0 to 3) in the study eye.
Lasso di tempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Change in signs on a 4-point scale (0 to 3) in the study eye. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline at week 6 and 12 in the QoL scores assessed by the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ-S) (assessed in the adult cohort only)
Lasso di tempo: Baseline and at Week 6 and Week 12.
|
Standardized Rhinoconjunctivitis QoL Questionnaire (RQLQ[S]) is a validated questionnaire that assesses QoL specifically in patients with rhinoconjunctivitis. There are 28 questions, which are categorized under 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Each question is scored on a 7-point scale from no impairment (score 0) to severe impairment (score 6). |
Baseline and at Week 6 and Week 12.
|
|
Patient Global Impression of Change (PGIC) at week 6 and week 12 (assessed in the adult cohort only)
Lasso di tempo: At week 6 and week 12.
|
PGIC is a short questionnaire used to assess how a participant perceives changes in their condition following treatment, on a scale ranging from 1 to 7. |
At week 6 and week 12.
|
|
Number of Participants receiving rescue medication over time after week 6
Lasso di tempo: Week 6 to Week 12
|
Participants who received rescued medication over time after week 6 (visit 4). |
Week 6 to Week 12
|
|
Number of participants with treatment-emergent adverse events and serious adverse events (SAEs)
Lasso di tempo: Up to Week 16
|
Any adverse events occurring or worsening after the first administration of investigational product is classified as "treatment-emergent" adverse events and does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important. |
Up to Week 16
|
|
Change from baseline over time in best corrected distance visual acuity (BCDVA) in each eye.
Lasso di tempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Best corrected visual acuity (BCDVA) is determined by careful refraction according to the standard protocol for refraction. BCDVA is measured by Early Treatment of Diabetic Retinopathy Study chart. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline at week 12 in corneal endothelial cell density in each eye (only at selected sites that have the required equipment).
Lasso di tempo: Baseline and at week 12
|
Corneal central region endothelial cell density will be determined for each eye using specular microscopy and expressed as the number of cells/mm2 using the Cell Density readout provided by the software. |
Baseline and at week 12
|
|
Change from baseline at week 12 in dilated fundus exam in each eye
Lasso di tempo: Baseline and at week 12
|
After specular microscopy, mydriatic drops will be instilled in both eyes and once adequate dilation is achieved, a fundal exam shall be performed to examine the vitreous, retina, and optic nerve. |
Baseline and at week 12
|
|
Change from baseline over time in intraocular pressure in each eye.
Lasso di tempo: Baseline and at Week 6 and Week 12
|
IOP will be assessed by tonometry for each eye and will be measured in mmHg. |
Baseline and at Week 6 and Week 12
|
|
Number of participants discontinued due to tolerability during the treatment period
Lasso di tempo: Baseline to week 12
|
Treatment discontinuation rate due to tolerability. |
Baseline to week 12
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Organizzazione della polmonite
- Malattie del sistema immunitario
- Malattie delle vie respiratorie
- Malattie polmonari
- Malattie bronchiali
- Malattie polmonari, ostruttive
- Bronchiolite obliterante
- Bronchiolite
- Bronchite
- Malattia del trapianto contro l'ospite
- Sindrome da bronchiolite obliterante
- Soluzioni farmaceutiche
- Preparati farmaceutici
- Azioni farmacologiche
- Azioni e usi chimici
- Usi terapeutici
- Soluzioni
- Usi speciali di sostanze chimiche
- Soluzioni oftalmiche
- desametasone 21-fosfato
Altri numeri di identificazione dello studio
- ICY-AKC-301
- 2025-522291-83-00 (Ctis)
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .